- Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
- Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
- Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
- Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
- Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
- Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
- Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
- Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
- Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
More ▼
Key statistics
On Thursday, Pharvaris NV (PHVS:NSQ) closed at 16.81, 105.00% above the 52 week low of 8.20 set on Jun 07, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.61 |
---|---|
High | 17.12 |
Low | 15.84 |
Bid | 6.73 |
Offer | 26.72 |
Previous close | 16.81 |
Average volume | 36.90k |
---|---|
Shares outstanding | 53.82m |
Free float | 32.83m |
P/E (TTM) | -- |
Market cap | 1.02bn USD |
EPS (TTM) | -2.58 USD |
Data delayed at least 15 minutes, as of Jun 06 2024 21:00 BST.
More ▼